Jazz Pharmaceuticals Plc Stock Working Capital

JAZZ Stock

USD 124.34 2.33 1.84%

Jazz Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.

	Last Reported	Projected for Next Year
Net Working Capital	1.9 B	1.6 B
Change In Working Capital	-204.4 M	-194.2 M

Net Working Capital is likely to drop to about 1.6 B in 2024. Change In Working Capital is likely to rise to about (194.2 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Jazz Pharmaceuticals PLC Company Working Capital Analysis

Jazz Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Jazz Pharmaceuticals Working Capital

1.9 B

Most of Jazz Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Jazz Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Jazz Pharmaceuticals is extremely important. It helps to project a fair market value of Jazz Stock properly, considering its historical fundamentals such as Working Capital. Since Jazz Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jazz Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jazz Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.91	0.96	0.75	0.96	0.98	0.98	0.99	0.11	0.98	0.93	0.98	0.95	0.6	0.63	0.5	-0.88	0.91	0.65	0.96	-0.13	0.9	0.69	0.82	-0.56
Total Stockholder Equity	0.91		0.78	0.93	0.81	0.8	0.89	0.91	0.44	0.82	0.91	0.85	0.9	0.52	0.57	0.65	-0.64	0.88	0.48	0.77	-0.26	0.7	0.76	0.82	-0.45
Net Debt	0.96	0.78		0.59	0.96	0.99	0.92	0.95	-0.08	0.99	0.82	0.98	0.9	0.52	0.54	0.34	-0.96	0.85	0.62	0.97	-0.1	0.94	0.61	0.75	-0.51
Retained Earnings	0.75	0.93	0.59		0.61	0.61	0.74	0.76	0.6	0.63	0.76	0.69	0.81	0.41	0.44	0.59	-0.44	0.77	0.36	0.57	-0.39	0.48	0.73	0.71	-0.3
Accounts Payable	0.96	0.81	0.96	0.61		0.97	0.96	0.95	-0.06	0.98	0.88	0.94	0.94	0.66	0.66	0.39	-0.9	0.84	0.67	0.98	0.02	0.92	0.69	0.75	-0.64
Long Term Debt	0.98	0.8	0.99	0.61	0.97		0.95	0.96	-0.07	1.0	0.86	0.98	0.9	0.54	0.57	0.4	-0.95	0.87	0.66	0.98	-0.1	0.94	0.61	0.76	-0.54
Net Receivables	0.98	0.89	0.92	0.74	0.96	0.95		0.97	0.14	0.96	0.96	0.92	0.94	0.67	0.72	0.47	-0.83	0.88	0.72	0.96	-0.04	0.87	0.71	0.84	-0.64
Good Will	0.99	0.91	0.95	0.76	0.95	0.96	0.97		0.08	0.97	0.9	0.98	0.94	0.59	0.61	0.58	-0.89	0.9	0.68	0.94	-0.19	0.86	0.67	0.76	-0.55
Short Term Investments	0.11	0.44	-0.08	0.6	-0.06	-0.07	0.14	0.08		-0.05	0.32	-0.02	0.14	0.01	0.18	0.19	0.32	0.22	-0.16	-0.08	-0.17	-0.07	0.5	0.48	0.05
Total Liab	0.98	0.82	0.99	0.63	0.98	1.0	0.96	0.97	-0.05		0.88	0.98	0.91	0.59	0.62	0.41	-0.94	0.87	0.69	0.99	-0.07	0.94	0.62	0.77	-0.58
Total Current Assets	0.93	0.91	0.82	0.76	0.88	0.86	0.96	0.9	0.32	0.88		0.83	0.86	0.65	0.76	0.49	-0.68	0.86	0.62	0.88	0.01	0.82	0.71	0.92	-0.62
Intangible Assets	0.98	0.85	0.98	0.69	0.94	0.98	0.92	0.98	-0.02	0.98	0.83		0.93	0.51	0.51	0.47	-0.94	0.88	0.6	0.94	-0.2	0.89	0.63	0.72	-0.48
Property Plant Equipment	0.95	0.9	0.9	0.81	0.94	0.9	0.94	0.94	0.14	0.91	0.86	0.93		0.62	0.59	0.44	-0.82	0.87	0.59	0.9	-0.18	0.81	0.77	0.74	-0.56
Current Deferred Revenue	0.6	0.52	0.52	0.41	0.66	0.54	0.67	0.59	0.01	0.59	0.65	0.51	0.62		0.95	0.15	-0.49	0.42	0.74	0.68	0.47	0.49	0.45	0.45	-0.93
Short Term Debt	0.63	0.57	0.54	0.44	0.66	0.57	0.72	0.61	0.18	0.62	0.76	0.51	0.59	0.95		0.16	-0.45	0.48	0.72	0.7	0.5	0.55	0.48	0.63	-0.91
Common Stock	0.5	0.65	0.34	0.59	0.39	0.4	0.47	0.58	0.19	0.41	0.49	0.47	0.44	0.15	0.16		-0.32	0.62	0.35	0.32	-0.45	0.27	0.34	0.32	-0.05
Net Tangible Assets	-0.88	-0.64	-0.96	-0.44	-0.9	-0.95	-0.83	-0.89	0.32	-0.94	-0.68	-0.94	-0.82	-0.49	-0.45	-0.32		-0.76	-0.65	-0.93	0.1	-0.89	-0.46	-0.55	0.47
Capital Surpluse	0.91	0.88	0.85	0.77	0.84	0.87	0.88	0.9	0.22	0.87	0.86	0.88	0.87	0.42	0.48	0.62	-0.76		0.51	0.82	-0.26	0.86	0.71	0.83	-0.28
Deferred Long Term Liab	0.65	0.48	0.62	0.36	0.67	0.66	0.72	0.68	-0.16	0.69	0.62	0.6	0.59	0.74	0.72	0.35	-0.65	0.51		0.73	0.16	0.52	0.35	0.38	-0.73
Long Term Debt Total	0.96	0.77	0.97	0.57	0.98	0.98	0.96	0.94	-0.08	0.99	0.88	0.94	0.9	0.68	0.7	0.32	-0.93	0.82	0.73		0.05	0.93	0.61	0.76	-0.67
Short Long Term Debt	-0.13	-0.26	-0.1	-0.39	0.02	-0.1	-0.04	-0.19	-0.17	-0.07	0.01	-0.2	-0.18	0.47	0.5	-0.45	0.1	-0.26	0.16	0.05		0.05	-0.11	0.04	-0.51
Net Invested Capital	0.9	0.7	0.94	0.48	0.92	0.94	0.87	0.86	-0.07	0.94	0.82	0.89	0.81	0.49	0.55	0.27	-0.89	0.86	0.52	0.93	0.05		0.57	0.81	-0.44
Long Term Investments	0.69	0.76	0.61	0.73	0.69	0.61	0.71	0.67	0.5	0.62	0.71	0.63	0.77	0.45	0.48	0.34	-0.46	0.71	0.35	0.61	-0.11	0.57		0.7	-0.38
Net Working Capital	0.82	0.82	0.75	0.71	0.75	0.76	0.84	0.76	0.48	0.77	0.92	0.72	0.74	0.45	0.63	0.32	-0.55	0.83	0.38	0.76	0.04	0.81	0.7		-0.41
Capital Stock	-0.56	-0.45	-0.51	-0.3	-0.64	-0.54	-0.64	-0.55	0.05	-0.58	-0.62	-0.48	-0.56	-0.93	-0.91	-0.05	0.47	-0.28	-0.73	-0.67	-0.51	-0.44	-0.38	-0.41

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Jazz Pharmaceuticals

Working Capital Over Time

Jazz Capital Surpluse

Capital Surpluse

2.16 Billion

At this time, Jazz Pharmaceuticals' Capital Surpluse is fairly stable compared to the past year.

According to the company's disclosures, Jazz Pharmaceuticals PLC has a Working Capital of 1.9 B. This is 346.08% higher than that of the Pharmaceuticals sector and 252.52% higher than that of the Health Care industry. The working capital for all United States stocks is 28.45% lower than that of the firm.

Jazz Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.

Jazz Pharmaceuticals is currently under evaluation in working capital category among its peers.

Jazz Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jazz Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jazz Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Jazz Fundamentals

	Return On Equity	0.12
	Return On Asset	0.0462
	Profit Margin	0.12 %
	Operating Margin	0.25 %
	Current Valuation	11.24 B
	Shares Outstanding	60.45 M
	Shares Owned By Insiders	2.93 %
	Shares Owned By Institutions	98.79 %
	Number Of Shares Shorted	3.59 M
	Price To Earning	35.18 X
	Price To Book	1.84 X
	Price To Sales	1.92 X
	Revenue	3.83 B
	Gross Profit	3.39 B
	EBITDA	1.45 B
	Net Income	414.83 M
	Cash And Equivalents	899.36 M
	Cash Per Share	14.28 X
	Total Debt	5.79 B
	Debt To Equity	2.12 %
	Current Ratio	3.16 X
	Book Value Per Share	69.01 X
	Cash Flow From Operations	1.09 B
	Short Ratio	7.01 X
	Earnings Per Share	7.06 X
	Price To Earnings To Growth	0.94 X
	Target Price	177.53
	Number Of Employees	2.8 K
	Beta	0.57
	Market Capitalization	7.66 B
	Total Asset	11.39 B
	Retained Earnings	878.66 M
	Working Capital	1.9 B
	Current Asset	1.26 B
	Current Liabilities	226.64 M
	Net Asset	11.39 B

About Jazz Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC